Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Stateside's Canadian Microcap Board -- Ignore unavailable to you. Want to Upgrade?

To: ayeyou who wrote (1559)	4/5/2016 5:17:37 PM
From: Dave@SI	Read Replies (1) \| Respond to of 1728

If you were looking for possible slippage, perhaps also worth a highlight is (re CRO partner) "The company is at the final stages of negotiations and hopes to report further on this within the coming weeks". I do wonder about the PP imminence. That first sentence with "believes it will be in a position to launch" would be unreasonably miss-leading if they don't have good grounds to believe they will have enough cash to start (but not complete)? Maybe they have a non-brokered placement all agreed, but otherwise I think they've got enough cash for now, or a grant perhaps (unlikely). My main problem is the time (investor boredom) until we get to some (interim) results. As per this message quoting the BioNap article, "If BriaCell could see some biomarker/outcome correlation then maybe the wait until "we should see data roughly 15-18 months later - so likely during the second half of 2017. " might be shortened." So we have seen an effect of the biomarker work, but what else is going to generate some enthusiasm? Biotech's often take longer than drill/drill/drill etc! Note that the Jan BioNap article also mentioned the BriDiag work somewhat presciently "However, one thing I did find very interesting is that the companion diagnostic is further along in development than I suspected." And yes I also wish I had sold (half at least) on the spike, I could have got 90% back if I'd had picked the top. BTW, BioNap also priced the trial at $3-5m (err cheap?), anyone got a better figure, I can't remember seeing anything directly from the company.